The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs

被引：41

作者：

Bernstein, David I. ^{[1
]}

Farley, Nicholas ^{[1
]}

Bravo, Fernando J. ^{[1
]}

Earwood, Julie ^{[1
]}

McNeal, Monica ^{[1
]}

Fairman, Jeff ^{[2
]}

Cardin, Rhonda ^{[1
]}

机构：

[1] Univ Cincinnati, Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA

[2] Juvaris BioTherapeut Inc, Burlingame, CA USA

来源：

VACCINE | 2010年 / 28卷 / 21期

关键词：

HSV vaccine; Adjuvant; Genital herpes; Guinea pig; CLDC; RECURRENT GENITAL HERPES; VIRUS TYPE-2; DNA COMPLEXES; IMMUNOTHERAPY; TRANSMISSION; IMMUNIZATION; PREVENTION; INFECTION; DELIVERY; TRIAL;

D O I：

10.1016/j.vaccine.2009.10.025

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposorne-DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2 + CLDC was compared to gD2 + MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：3748 / 3753

页数：6

共 25 条

[1]

Bernstein D I, 2001, Herpes, V8, P8

[2] Potent Adjuvant Activity of Cationic Liposome-DNA Complexes for Genital Herpes Vaccines [J].

Bernstein, David I. ;

Cardin, Rhonda D. ;

Bravo, Fernando J. ;

Strasser, Jane E. ;

Farley, Nicholas ;

Chalk, Claudia ;

Lay, Marla ;

Fairman, Jeff .

CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (05) :699-705

[3] Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected [J].

Bourne, N ;

Milligan, GN ;

Stanberry, LR ;

Stegall, R ;

Pyles, RB .

JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (12) :2117-2123

[4] Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs [J].

Bourne, N ;

Bravo, FJ ;

Francotte, M ;

Bernstein, DI ;

Myers, MG ;

Slaoui, M ;

Stanberry, LR .

JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (04) :542-549

[5] Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection - Two randomized controlled trials [J].

Corey, L ;

Langenberg, AGM ;

Ashley, R ;

Sekulovich, RE ;

Izu, AE ;

Douglas, JM ;

Handsfield, HH ;

Warren, T ;

Marr, L ;

Tyring, S ;

DiCarlo, R ;

Adimora, AA ;

Leone, P ;

Dekker, CL ;

Burke, RL ;

Leong, WP ;

Straus, SE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (04) :331-340

[6] Systemic and local interferon γ gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice [J].

Dow, SW ;

Schwarze, J ;

Heath, TD ;

Potter, TA ;

Gelfand, EW .

HUMAN GENE THERAPY, 1999, 10 (12) :1905-1914

[7]

Dow SW, 1999, J IMMUNOL, V163, P1552

[8]

FAIRMAN J, 2008, HUM VACCIN, V5

[9]

Freimark BD, 1998, J IMMUNOL, V160, P4580

[10] Genital herpes [J].

Gupta, Rachna ;

Warren, Terri ;

Wald, Anna .

LANCET, 2007, 370 (9605) :2127-2137

← 1 2 3 →